Synopsis
Synopsis
0
KDMF
0
VMF
0
FDF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Desiflu
2. Du 23000
3. Du-23000
4. Du23000
5. Dumirox
6. Faverin
7. Fevarin
8. Floxyfral
9. Fluvoxadura
10. Fluvoxamin Al
11. Fluvoxamin Beta
12. Fluvoxamin Neuraxpharm
13. Fluvoxamin Ratiopharm
14. Fluvoxamin Stada
15. Fluvoxamin-neuraxpharm
16. Fluvoxamin-ratiopharm
17. Fluvoxamina Geminis
18. Fluvoxamine
19. Fluvoxamine Maleate, (e)-isomer
20. Fluvoxamine, (z)-isomer
21. Geminis, Fluvoxamina
22. Luvox
23. Novo Fluvoxamine
24. Novo-fluvoxamine
25. Nu Fluvoxamine
26. Nu-fluvoxamine
27. Pms Fluvoxamine
28. Pms-fluvoxamine
29. Ratio Fluvoxamine
30. Ratio-fluvoxamine
1. Luvox
2. 61718-82-9
3. Fevarin
4. Faverin
5. Luvox Cr
6. Du23000
7. Fluvoxamine (maleate)
8. Du-23000
9. Fluvoxamine Hydrogenmaleate
10. 54739-20-7
11. Nsc-759602
12. 5lgn83g74v
13. (z)-but-2-enedioic Acid;2-[(e)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
14. 1-pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (e)-, (z)-2-butenedioate (1:1)
15. Fluvoxaminemaleate
16. Floxyfral
17. (e)-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) Oxime Maleate
18. Mk-264
19. (e)-5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone-o-(2-aminoethyl)oxime Maleate
20. Fluvoxamine Maleate [usan]
21. (2z)-but-2-enedioic Acid; (e)-(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine
22. Smr000466268
23. Smr000653482
24. Sr-01000075613
25. Sme 3110
26. Unii-5lgn83g74v
27. Depromel
28. Fluvoxamine Maleate [usan:usp]
29. Luvox (tn)
30. Nsc 309469
31. Fluvoxamine Maleate, Solid
32. 5-methoxy-4'-trifluoromethylvalerophenone (e)-o-2-aminoethyloxime Monomaleate
33. Fluvoxamine Maleate- Bio-x
34. 5-methoxy-4'-(trifluoromethyl)valerophenone (e)-o-(2-aminoethyl)oxime, Maleate (1:1)
35. Chembl1409
36. Schembl35225
37. Mls000028469
38. Mls000758271
39. Mls001076285
40. Mls001304717
41. Mls001401391
42. Chebi:5139
43. Dtxsid3042558
44. Fluvoxamine Maleate [mi]
45. Hy-b0103a
46. Fluvoxamine Maleate [jan]
47. Fluvoxamine Maleate (jp17/usp)
48. Hms1571g11
49. Hms2098g11
50. Hms3261d11
51. Hms3412a13
52. Hms3676a13
53. Hms3715g11
54. Hms3884k11
55. Pharmakon1600-01505604
56. Fluvoxamine Maleate [vandf]
57. (2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine; But-2-enedioic Acid
58. Fluvoxamine Maleate [mart.]
59. Sme-3110
60. Tox21_500495
61. Fluvoxamine Maleate [usp-rs]
62. Fluvoxamine Maleate [who-dd]
63. Mfcd00269809
64. Nsc309469
65. Nsc759602
66. S1336
67. Akos015961142
68. Ac-9541
69. Ccg-213494
70. Cs-1839
71. Nsc 759602
72. Nsc-309469
73. Fluvoxamine Maleate [orange Book]
74. Ncgc00093897-01
75. Ncgc00093897-02
76. Ncgc00261180-01
77. (e)-5-methoxy-1-(4-(trifluoromethyl)phenyl)-1-pentanone O-(2-aminoethyl)oxime (z)-2-butenedioate (1:1)
78. As-11790
79. Bf164482
80. Fluvoxamine Maleate [ep Monograph]
81. Smr000058449
82. Fluvoxamine Maleate [usp Monograph]
83. Eu-0100495
84. F0858
85. D00824
86. F 2802
87. 739f183
88. A833394
89. Sr-01000075613-1
90. Sr-01000075613-3
91. Sr-01000075613-4
92. Sr-01000075613-6
93. Fluvoxamine Maleate, British Pharmacopoeia (bp) Reference Standard
94. Fluvoxamine Maleate, European Pharmacopoeia (ep) Reference Standard
95. Fluvoxamine Maleate, United States Pharmacopeia (usp) Reference Standard
96. (e)-5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-aminoethyl)oxime Maleate
97. 5-methoxy-1-(4-trifluoromethyl-phenyl)-pentan-1-one O-(2-amino-ethyl)-oxime Maleate
98. Fluvoxamine For System Suitability, European Pharmacopoeia (ep) Reference Standard
99. Fluvoxamine Maleate, 1.0 Mg/ml In Methanol ((as Free Base)), Certified Reference Material
100. Fluvoxamine Maleate, Pharmaceutical Secondary Standard; Certified Reference Material
101. (z)-2-butenedioic Acid; 2-[(e)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
102. (z)-but-2-enedioic Acid; 2-[(e)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
103. 1-pentanone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-,o-(2-aminoethyl)oxime, (1e)-, (2z)-2-butenedioate (1:1)
104. 2-[({(1e)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine (2z)-but-2-enedioate
105. 5-methoxy-4'-(trifluoromethyl)valerophenone-(e)-o-(2-aminoethyl)oxime Maleate (1:1)
Molecular Weight | 434.4 g/mol |
---|---|
Molecular Formula | C19H25F3N2O6 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 11 |
Exact Mass | 434.16647101 g/mol |
Monoisotopic Mass | 434.16647101 g/mol |
Topological Polar Surface Area | 131 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 446 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Fluvoxamine maleate |
PubMed Health | Fluvoxamine (By mouth) |
Drug Classes | Antidepressant, Central Nervous System Agent |
Drug Label | Fluvoxamine maleate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) belonging to a new chemical series, the 2-aminoethyl oxime ethers of aralkylketones. It is chemically unrelated to other SSRIs and clomipramine. It is chemically designated... |
Active Ingredient | Fluvoxamine maleate |
Dosage Form | Tablet; Capsule, extended release |
Route | Oral |
Strength | 25mg; 150mg; 100mg; 50mg |
Market Status | Prescription |
Company | Anchen Pharms; Teva; Apotex; Sandoz; Actavis Elizabeth; Mylan; Barr |
2 of 6 | |
---|---|
Drug Name | Luvox |
PubMed Health | Fluvoxamine (By mouth) |
Drug Classes | Antidepressant, Central Nervous System Agent |
Drug Label | Fluvoxamine maleate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) belonging to a new chemical series, the 2-aminoethyl oxime ethers of aralkylketones. It is chemically unrelated to other SSRIs and clomipramine. It is chemically designated... |
Active Ingredient | Fluvoxamine maleate |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 25mg; 100mg; 50mg |
Market Status | Prescription |
Company | Ani Pharms; Jazz |
3 of 6 | |
---|---|
Drug Name | Luvox cr |
Drug Label | LUVOX CR is an extended-release capsule for oral administration that contains fluvoxamine maleate, a selective serotonin (5-HT) reuptake inhibitor (SSRI) belonging to the chemical series, the 2-aminoethyl oxime ethers of aralkylketones.... |
Active Ingredient | Fluvoxamine maleate |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 150mg; 100mg |
Market Status | Prescription |
Company | Jazz Pharms |
4 of 6 | |
---|---|
Drug Name | Fluvoxamine maleate |
PubMed Health | Fluvoxamine (By mouth) |
Drug Classes | Antidepressant, Central Nervous System Agent |
Drug Label | Fluvoxamine maleate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) belonging to a new chemical series, the 2-aminoethyl oxime ethers of aralkylketones. It is chemically unrelated to other SSRIs and clomipramine. It is chemically designated... |
Active Ingredient | Fluvoxamine maleate |
Dosage Form | Tablet; Capsule, extended release |
Route | Oral |
Strength | 25mg; 150mg; 100mg; 50mg |
Market Status | Prescription |
Company | Anchen Pharms; Teva; Apotex; Sandoz; Actavis Elizabeth; Mylan; Barr |
5 of 6 | |
---|---|
Drug Name | Luvox |
PubMed Health | Fluvoxamine (By mouth) |
Drug Classes | Antidepressant, Central Nervous System Agent |
Drug Label | Fluvoxamine maleate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) belonging to a new chemical series, the 2-aminoethyl oxime ethers of aralkylketones. It is chemically unrelated to other SSRIs and clomipramine. It is chemically designated... |
Active Ingredient | Fluvoxamine maleate |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 25mg; 100mg; 50mg |
Market Status | Prescription |
Company | Ani Pharms; Jazz |
6 of 6 | |
---|---|
Drug Name | Luvox cr |
Drug Label | LUVOX CR is an extended-release capsule for oral administration that contains fluvoxamine maleate, a selective serotonin (5-HT) reuptake inhibitor (SSRI) belonging to the chemical series, the 2-aminoethyl oxime ethers of aralkylketones.... |
Active Ingredient | Fluvoxamine maleate |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 150mg; 100mg |
Market Status | Prescription |
Company | Jazz Pharms |
Anti-Anxiety Agents
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)
Antidepressive Agents, Second-Generation
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)
Cytochrome P-450 CYP1A2 Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inhibitors.)
Cytochrome P-450 CYP2C19 Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2C19. (See all compounds classified as Cytochrome P-450 CYP2C19 Inhibitors.)
Selective Serotonin Reuptake Inhibitors
Compounds that specifically inhibit the reuptake of serotonin in the brain. (See all compounds classified as Selective Serotonin Reuptake Inhibitors.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20569
Submission : 2007-06-01
Status : Active
Type : II
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-01-04
Pay. Date : 2017-10-18
DMF Number : 29582
Submission : 2015-07-22
Status : Active
Type : II
Certificate Number : CEP 2014-089 - Rev 04
Issue Date : 2024-09-27
Type : Chemical
Substance Number : 1977
Status : Valid
Date of Issue : 2022-08-25
Valid Till : 2025-07-02
Written Confirmation Number : WC-0195
Address of the Firm :
NDC Package Code : 76072-1003
Start Marketing Date : 2016-04-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14511
Submission : 1999-10-29
Status : Active
Type : II
NDC Package Code : 53296-0043
Start Marketing Date : 2010-04-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (75kg/75kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13913
Submission : 1998-12-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39019
Submission : 2023-10-18
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13892
Submission : 1998-12-10
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20569
Submission : 2007-06-01
Status : Active
Type : II
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2018-01-04
Pay. Date : 2017-10-18
DMF Number : 29582
Submission : 2015-07-22
Status : Active
Type : II
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14511
Submission : 1999-10-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13913
Submission : 1998-12-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13957
Submission : 1999-01-22
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-09-15
Pay. Date : 2014-06-05
DMF Number : 14529
Submission : 1999-11-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13892
Submission : 1998-12-10
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25201
Submission : 2011-08-05
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-09-24
Pay. Date : 2021-09-21
DMF Number : 16174
Submission : 2002-09-24
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5169
Submission : 1983-12-15
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Fluvoxamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fluvoxamine, including repackagers and relabelers. The FDA regulates Fluvoxamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fluvoxamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fluvoxamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Fluvoxamine supplier is an individual or a company that provides Fluvoxamine active pharmaceutical ingredient (API) or Fluvoxamine finished formulations upon request. The Fluvoxamine suppliers may include Fluvoxamine API manufacturers, exporters, distributors and traders.
click here to find a list of Fluvoxamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fluvoxamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Fluvoxamine active pharmaceutical ingredient (API) in detail. Different forms of Fluvoxamine DMFs exist exist since differing nations have different regulations, such as Fluvoxamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fluvoxamine DMF submitted to regulatory agencies in the US is known as a USDMF. Fluvoxamine USDMF includes data on Fluvoxamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fluvoxamine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fluvoxamine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Fluvoxamine Drug Master File in Japan (Fluvoxamine JDMF) empowers Fluvoxamine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Fluvoxamine JDMF during the approval evaluation for pharmaceutical products. At the time of Fluvoxamine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Fluvoxamine suppliers with JDMF on PharmaCompass.
A Fluvoxamine CEP of the European Pharmacopoeia monograph is often referred to as a Fluvoxamine Certificate of Suitability (COS). The purpose of a Fluvoxamine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Fluvoxamine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Fluvoxamine to their clients by showing that a Fluvoxamine CEP has been issued for it. The manufacturer submits a Fluvoxamine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Fluvoxamine CEP holder for the record. Additionally, the data presented in the Fluvoxamine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Fluvoxamine DMF.
A Fluvoxamine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Fluvoxamine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Fluvoxamine suppliers with CEP (COS) on PharmaCompass.
A Fluvoxamine written confirmation (Fluvoxamine WC) is an official document issued by a regulatory agency to a Fluvoxamine manufacturer, verifying that the manufacturing facility of a Fluvoxamine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Fluvoxamine APIs or Fluvoxamine finished pharmaceutical products to another nation, regulatory agencies frequently require a Fluvoxamine WC (written confirmation) as part of the regulatory process.
click here to find a list of Fluvoxamine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fluvoxamine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fluvoxamine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fluvoxamine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fluvoxamine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fluvoxamine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fluvoxamine suppliers with NDC on PharmaCompass.
Fluvoxamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fluvoxamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fluvoxamine GMP manufacturer or Fluvoxamine GMP API supplier for your needs.
A Fluvoxamine CoA (Certificate of Analysis) is a formal document that attests to Fluvoxamine's compliance with Fluvoxamine specifications and serves as a tool for batch-level quality control.
Fluvoxamine CoA mostly includes findings from lab analyses of a specific batch. For each Fluvoxamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fluvoxamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Fluvoxamine EP), Fluvoxamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fluvoxamine USP).
LOOKING FOR A SUPPLIER?